Literature DB >> 32974912

Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study.

J W Frew1, K Navrazhina1,2, M Sullivan-Whalen1, P Gilleaudeau1, S Garcet1, J G Krueger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32974912     DOI： 10.1111/bjd.19478

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  Rapid resolution of pyoderma gangrenosum with brodalumab therapy.

Authors:  Michael W Tee; Andrew B Avarbock; Jonathan Ungar; John W Frew
Journal:  JAAD Case Rep       Date:  2020-09-14

Review 2.  Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions.

Authors:  Simon W Jiang; Melodi Javid Whitley; Paula Mariottoni; Tarannum Jaleel; Amanda S MacLeod
Journal:  JID Innov       Date:  2021-01-12

Review 3.  New and Emerging Targeted Therapies for Hidradenitis Suppurativa.

Authors:  Adela Markota Čagalj; Branka Marinović; Zrinka Bukvić Mokos
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

Review 4.  Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.

Authors:  Zuzanna Świerczewska; Miłosz Lewandowski; Agnieszka Surowiecka; Wioletta Barańska-Rybak
Journal:  Int J Mol Sci       Date:  2022-08-26       Impact factor: 6.208

Review 5.  Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.

Authors:  Pim Aarts; Koen Dudink; Allard R J V Vossen; Kelsey R van Straalen; Christine B Ardon; Errol P Prens; Hessel H van der Zee
Journal:  Drugs       Date:  2021-07-20       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.